Taken together, our data suggested that miR-129-2 function as a tumor suppressor in HCC cells by directly targeting HMGB1 and is down-regulated by DNA methylation, which may provide a novel therapeutic strategy for treatment of HCC. Here, HMGB1 is linked to hepatocellular carcinoma.